Tandem Diabetes Care, Inc. (TNDM) Stock
TNDM Key Statistics
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
CEO: John F. Sheridan. Company website
TNDM — Frequently Asked Questions
What is the TNDM stock price today?
Tandem Diabetes Care, Inc. (TNDM) trades at $16.87, down 2.09% on the day, as of Sep 20, 2026 15:01 UTC.
What is Tandem Diabetes Care, Inc.'s market cap?
Tandem Diabetes Care, Inc. has a market capitalisation of $1.16B, calculated from the live TNDM share price and shares outstanding.
What is the P/E ratio of TNDM?
TNDM has no meaningful price-to-earnings ratio: Tandem Diabetes Care, Inc. lost $0.93 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Tandem Diabetes Care, Inc. make?
Tandem Diabetes Care, Inc. generated revenue of $1.04B over the trailing twelve months, which puts the stock at 1.11 times sales.
What is the 52-week range for TNDM?
TNDM has traded between $11.46 and $29.65 over the past 52 weeks, and the last price is 43.1% below that high.
Is Tandem Diabetes Care, Inc. profitable?
No. Tandem Diabetes Care, Inc. is loss-making, with a net margin of -6.08% over the trailing twelve months.
What is the analyst price target for TNDM?
Wall Street analysts rate TNDM Buy, with an average price target of $30.17, 78.8% above the current price.
What sector is Tandem Diabetes Care, Inc. in?
Tandem Diabetes Care, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Tandem Diabetes Care, Inc.?
John F. Sheridan is the chief executive of Tandem Diabetes Care, Inc., which employs 2,500 people.
Where can I track TNDM in real time?
QFI Terminal shows TNDM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TNDM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TNDM in Terminal See plans